Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Nov. 30, 2016
Nov. 30, 2015
Statement of Cash Flows [Abstract]    
Net (loss) income $ (1,320,800) $ 8,106,343
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization expense 286,650 241,208
Impairment of investment in Saneron   684,000
Impairment of goodwill and intangible assets 1,989,089  
Compensatory element of stock options 1,772,306 602,978
Provision for doubtful accounts 630,113 699,682
Equity in losses of affiliate   18,824
Gain on extinguishment of debt (300,593)  
Loss on extinguishment of revenue sharing agreements 2,252,388  
Deferred income tax benefit (1,911,828) (7,369,513)
Amortization of debt issuance costs 48,435  
Changes in assets and liabilities:    
Accounts receivable (1,624,462) 313,936
Prepaid expenses 32,318 178,935
Inventory 114,466 117,231
Other current assets 9,944 (29,008)
Deposits and other assets, net 15,111 11,243
Accounts payable 329,560 335,709
Accrued expenses 648,842 (540,246)
Deferred revenue 2,016,436 1,480,140
Net cash provided by operating activities 4,987,975 4,851,462
Cash flows from investing activities:    
Release of restricted cash held in escrow 204,344 (203)
Purchases of property and equipment (342,982) (108,480)
Purchase of Prepacyte   (375,374)
Purchases of marketable securities and other investments, net (231,090) (235,292)
Net cash used in investing activities (369,728) (719,349)
Cash flows from financing activities:    
Extinguishment of revenue sharing agreements (3,400,000)  
Treasury stock purchases (10,806,409) (3,205,435)
Repayments of note payable (1,509,107) (123,633)
Proceeds from the exercise of stock options 40,340 69,850
Proceeds from note payable 10,783,433  
Issuance costs associated with the proceeds from the note payable (378,785)  
Net cash used in financing activities (5,270,528) (3,259,218)
Decrease in cash and cash equivalents (652,281) 872,895
Cash and cash equivalents - beginning of period 4,152,162 3,279,267
Cash and cash equivalents - end of period 3,499,881 4,152,162
Supplemental non-cash investing activities:    
Unrealized (loss) gain on marketable securities $ (135,524) 169,932
Increase of note payable in connection with the purchased business   1,300,000
Assumption of accrued expenses in connection with the purchased business   423,504
Decrease in prepaid expenses in connection with the purchased business   $ 104,000